Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making



Status:Recruiting
Conditions:Cancer, Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:23 - Any
Updated:3/7/2019
Start Date:March 31, 2017
End Date:December 31, 2019
Contact:Michael Donovan, PhD, MD
Email:michael.donovan@vigilantbiosciences.com
Phone:954-555-1212

Use our guide to learn which trials are right for you!

Clinical Evaluation of the OncAlert RAPID; Impact on Decision-Making

Objectives Validate the OncAlert RAPID Test, with an NPV ≥(1-prevalence).

Evaluate the independent and associated contribution of readily available clinical variables
including age, race, gender, HPV status, socioeconomic level, tobacco, and alcohol use with
the biopsy and test results.

Evaluate OncAlert RAPID Test results in patients without immediate biopsy, both at baseline
and scheduled follow-up visit (approximately 1-3 months), to assess impact on outcome.

Planned Number of Subjects 800 patients will be followed until pathology of clinically
directed incisional / diagnostic biopsy pathology report is received.

An additional 200 'non-biopsy subjects' will be followed then re-evaluated during a 1-3 month
clinic visit.

Additional follow up of subject data may continue for up to 2 years. Patient Population

Cohorts 1a and 1b:

Subjects with a clinical suspicion of oral potentially malignant disorders, oral or
oropharyngeal cancer, or both based in part on clinical examination, symptoms, clinical
history, suspicious lesion(s) in mouth without history of a prior biopsy.

- Cohort 1a: oral cavity

- Cohort 1b: oropharynx

Cohort 2:

Subjects with clinically indicated suspicion of disease but without immediate biopsy, both at
baseline and scheduled follow-up visit (approximately 1-3 months), Screen Fail Rate A 20%
Screen Fail Rate is anticipated. Investigational Product Name OncAlert Oral Cancer RAPID Test
(OncAlert RAPID) Methodology Overview Prospectively collect 5cc of normal saline after a
combination of swish, gargle and spit into the provided collection specimen cup. Specimens
will be collected at baseline (time of biopsy) as per standard practice at each site. The
OncAlert RAPID Test cassette is inserted into the specimen cup and read directly from the
cassette in 10 minutes. In addition, comprehensive clinical - pathology and patient
demographic features including age, gender, race, ethnicity, and all pathology biopsy results
will be collected. Any pertinent additional clinical data including HPV status, socioeconomic
status, smoking, drinking history, and pertinent features related to oral health will be
obtained. A central pathology review for all biopsy results will be performed and
incorporated into the final analyses.

Overview

The OncAlert Oral Cancer RAPID Test (OncAlert RAPID) is a qualitative point-of-care lateral
flow assay to aid in the decision to biopsy in patients with clinical features associated
with oral potentially malignant disorders and or oral/oropharyngeal cancer (i.e. head and
neck squamous cell carcinoma).

Proposed Intended Use Statement

The device measures soluble CD44 and total protein in saliva samples collected in saline. The
test is an adjunct to the biopsy decision process, and not intended as a screening or
stand-alone diagnostic assay. To be used in adults 23 years and older. Not intended for use
in pregnant women.

STUDY OBJECTIVES

The principal objectives of this study are to:

- Validate the OncAlert RAPID Test, with an NPV ≥ (1-prevalence),

- Evaluate OncAlert RAPID Test results in patients without immediate biopsy, both at
baseline and scheduled follow-up visit (approximately 1-3 months), to assess impact on
outcome,

- Evaluate the independent and associated contribution of readily available clinical
variables including age, race, gender, HPV status, socioeconomic level, tobacco, and
alcohol use with the biopsy and test results.

STUDY OVERVIEW

Study Approach

Prospectively collect 5cc of normal saline after a combination of swish, gargle and spit into
the provided collection specimen cup. 1cc will be removed and sequestered for subsequent
downstream analyses (Section 7). Specimens will be collected at baseline (time of biopsy) as
per standard practice at each site. The OncAlert RAPID Test cassette is inserted into the
specimen cup and read directly from the cassette in 10 minutes. In addition, acquire
comprehensive clinical - pathology and patient demographic features including age, gender,
race, ethnicity, and all pathology biopsy results. Also, obtain any pertinent additional
clinical data including HPV status, socioeconomic status, smoking, drinking history, and
pertinent features related to oral health. It is presumed that some patients within the
current biopsy protocol will undergo treatment as a result of the biopsy diagnosis. The
clinical-pathology data, when accessible, for these patients will be collected for subsequent
secondary analyses. A central pathology review for all biopsy results will be performed and
incorporated into the final analyses.

Study Duration

Cohorts 1a and 1b patients will be followed until pathology of clinically directed incisional
/ diagnostic biopsy pathology report is received.

Cohort 2 patients not having an initial incisional / diagnostic biopsy will have an
additional OncAlert RAPID test performed within 1-3 months of initial visit as per clinical
indications and followed as per 7.2.1, specifically if a biopsy is performed.

It is anticipated that the study will continue up to 1.5-years to collect all pertinent
clinical information on enrolled subjects.

Inclusion Criteria:

- 23 years of age or older

- A clinical suspicion of oral potentially malignant disorders, oral or oropharyngeal
cancer, or both based in part on clinical examination, symptoms, clinical history,
suspicious lesion(s) in mouth without history of a prior biopsy.

- The subject must be able to comprehend and sign an approved informed consent form and
other applicable study documents. Patients are eligible regardless of race, gender,
and ethnicity.

Exclusion Criteria:

- Prior history and/or diagnosis of any HN cancer/HNSCC of the oral cavity, oropharynx,
or hypopharynx including nasopharyngeal carcinoma.

- Prior treatment of HN cancer / HNSCC of the oral cavity, oropharynx, or hypopharynx
including nasopharyngeal carcinoma.

- Planned excisional biopsy for a diagnosis of HNSCC

- Clinical presentation without localizing findings

- Prior history of a salivary gland tumor

- Current and or prior diagnosis of cancer (note: other than basal and squamous cell
carcinoma of the skin) within the past 5 years.

- Pregnant
We found this trial at
24
sites
Boston, Massachusetts 02111
Phone: 617-636-2408
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
920 Madison Ave
Memphis, Tennessee 38163
1587
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
Principal Investigator: Timothy Meiller, DDS
Phone: 443-676-2403
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Beverly Hills, California 90211
22
mi
from 91732
Beverly Hills, CA
Click here to add this to my saved trials
Boston, Massachusetts 02215
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Chicago, Illinois 60657
Phone: 773-289-1823
1721
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Clive, Iowa 50325
Phone: 515-274-9136
1415
mi
from 91732
Clive, IA
Click here to add this to my saved trials
?
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Farmington, Connecticut 06030
Phone: 860-679-2952
2489
mi
from 91732
Farmington, CT
Click here to add this to my saved trials
Fort Worth, Texas 76109
Phone: 817-332-8848
?
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Greenville, North Carolina 27834
Phone: 252-737-7126
2290
mi
from 91732
Greenville, NC
Click here to add this to my saved trials
Kansas City, Missouri 64108
Phone: 816-235-2200
1341
mi
from 91732
Kansas City, MO
Click here to add this to my saved trials
La Mesa, California 91942
Phone: 619-647-6638
106
mi
from 91732
La Mesa, CA
Click here to add this to my saved trials
Loma Linda, California 92350
Phone: 909-558-8069
43
mi
from 91732
Loma Linda, CA
Click here to add this to my saved trials
Mansfield, Texas 76063
Phone: 972-731-7654
1207
mi
from 91732
Mansfield, TX
Click here to add this to my saved trials
New Hyde Park, New York 11040
2449
mi
from 91732
New Hyde Park, NY
Click here to add this to my saved trials
Plantation, Florida 33324
?
mi
from 91732
Plantation, FL
Click here to add this to my saved trials
Pompano Beach, Florida 33064
?
mi
from 91732
Pompano Beach, FL
Click here to add this to my saved trials
Port Saint Lucie, Florida 34952
?
mi
from 91732
Port Saint Lucie, FL
Click here to add this to my saved trials
Roseville, California 95661
370
mi
from 91732
Roseville, CA
Click here to add this to my saved trials
Sacramento, California 95815
363
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
736 South 900 East
Saint George, Utah 84790
Phone: 435-628-3334
325
mi
from 91732
Saint George, UT
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
?
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials